Phaseline

Companies › Etnova Therapeutics

Etnova Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ETN101
Multiple tyrosine kinase inhibitor targeting FLT3, KIT, VEGFR2, and PDGFRB
FLT3, KIT, VEGFR2, PDGFRBPhase 1Hepatocellular CarcinomaMar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06326502ETN101Phase 1Hepatocellular CarcinomaOncologyMar 2027

Targets

FLT3 (1) KIT (1) VEGFR2 (1) PDGFRB (1)

Companies with the same targets

Daiichi Sankyo Novartis Jiangsu HengRui Medicine Roche Chia Tai Tianqing Pharmaceutical Group Blueprint Medicines Deciphera Pharmaceuticals Gossamer Bio USA Advenchen Laboratories Taiho Pharmaceutical

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.